Spots Global Cancer Trial Database for ripretinib
Every month we try and update this database with for ripretinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | NCT03673501 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | NCT03673501 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib | NCT05734105 | GIST | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | GIST | DCC-3116 Ripretinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib | NCT04633122 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy | NCT05132738 | Gastrointestina... | Ripretinib trea... | 18 Years - 75 Years | RenJi Hospital | |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST | NCT04530981 | GIST - Gastroin... | Ripretinib Repaglinide | 18 Years - | Deciphera Pharmaceuticals LLC | |
| The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients With Advanced GISTs | NCT06431451 | Gastrointestina... | 18 Years - | First Affiliated Hospital, Sun Yat-Sen University | ||
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | NCT03673501 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST | NCT04530981 | GIST - Gastroin... | Ripretinib Repaglinide | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST | NCT04530981 | GIST - Gastroin... | Ripretinib Repaglinide | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib | NCT05734105 | GIST | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib | NCT04633122 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy | NCT05132738 | Gastrointestina... | Ripretinib trea... | 18 Years - 75 Years | RenJi Hospital | |
| Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy | NCT05132738 | Gastrointestina... | Ripretinib trea... | 18 Years - 75 Years | RenJi Hospital | |
| Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | NCT04148092 | GIST - Gastroin... | ripretinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST | NCT04530981 | GIST - Gastroin... | Ripretinib Repaglinide | 18 Years - | Deciphera Pharmaceuticals LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
